ErbB3/HER3

ErbB3 (HER3) is an unusual ERBB family member whose kinase domain is catalytically impaired but whose extracellular region binds neuregulins with the highest affinity in the family. Upon neuregulin engagement, HER3 heterodimerizes chiefly with HER2, and the partner kinase drives robust PI3K-AKT signaling through ERBB3's characteristic docking tyrosines. Frequent HER3 upregulation contributes to resistance against EGFR and HER2 targeted therapies. Patritumab deruxtecan, an HER3-directed antibody-drug conjugate, has advanced in lung and breast cancer trials, sustaining interest in recombinant ERBB3 reagents. Gene mutations in ERBB3 occur across cancers, and HER3 levels are being evaluated as pharmacodynamic biomarkers in neuregulin-driven settings.